ZOLGENSMA

Product Overview

About ZOLGENSMA

ZOLGENSMA is a groundbreaking gene therapy medicine that contains the active ingredient ONASEMNOGENE ABEPARVOVEC. It is specifically designed to treat spinal muscular atrophy (SMA), a severe and debilitating genetic disorder that affects muscle strength and movement. ZOLGENSMA works by replacing the faulty SMN1 gene, which is responsible for producing the survival motor neuron protein, essential for muscle function and strength.

Key Benefits & Uses

• Treatment of spinal muscular atrophy (SMA) in patients with a confirmed diagnosis
• Replacement of the faulty SMN1 gene to produce the survival motor neuron protein
• Potential to improve muscle strength, movement, and overall quality of life for SMA patients

Active Ingredient & Action

ONASEMNOGENE ABEPARVOVEC, the active ingredient in ZOLGENSMA, is a recombinant adeno-associated virus vector that delivers a functional copy of the human SMN1 gene to motor neuron cells. This gene transfer enables the production of the survival motor neuron protein, which is critical for maintaining muscle function and strength, thereby alleviating the symptoms of SMA.

Important Notes

Patients should consult their healthcare provider before receiving ZOLGENSMA, as it is a prescription-only medicine. It is essential to follow the recommended dosage and administration guidelines to minimize potential side effects. Additionally, patients should be monitored for any adverse reactions or changes in their condition after receiving ZOLGENSMA.